NUWE NUWELLIS INC

Nuwellis to Present at the Oppenheimer 33rd Annual Healthcare Conference

Nuwellis to Present at the Oppenheimer 33rd Annual Healthcare Conference

MINNEAPOLIS, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that Nestor Jaramillo, President and Chief Executive Officer, and Lynn Blake, Chief Financial Officer, will participate in the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023.

Nuwellis will give a corporate presentation on Tuesday, March 14, 2023, at 9:20 AM ET and host investor 1x1 meetings, which can be requested through Oppenheimer. The webcast presentation will be available for viewing on the Company's website at and will be archived and available for replay.

About Nuwellis

Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The Company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland.   For more information visit or visit us on and .

About the Aquadex SmartFlow® System 

The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies. 

CONTACTS

INVESTORS:

Vivian Cervantes

Gilmartin Group

MEDIA:

Annika Parish

Health+Commerce



EN
23/02/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NUWELLIS INC

 PRESS RELEASE

Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Stra...

Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy Appointment Strengthens Clinical Leadership in Precision Fluid Management and Acute Kidney Injury MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and criti...

 PRESS RELEASE

Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of ...

Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company’s board with complementary expertise in public company leadership, capital markets, and medical device commercialization. “These appointments reflect our c...

 PRESS RELEASE

Nuwellis, Inc. To Report Fourth Quarter and Full Year 2025 Financial R...

Nuwellis, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026 MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will release financial results for the fourth quarter and full year 2025 on March 10, 2026. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of th...

 PRESS RELEASE

Nuwellis Appoints Carisa Schultz as Chief Financial Officer

Nuwellis Appoints Carisa Schultz as Chief Financial Officer Schultz brings public company healthcare finance and medical technology experience to support Nuwellis’ next phase of growth MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) a medical technology company focused on advancing precision cardiorenal care, today announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2, 2026. Ms. Schultz brings extensive healthcare and public company finance leadership experience, most recently serving as Vice President of Finance at ...

 PRESS RELEASE

Nuwellis Announces $5 Million Private Placement and Warrant Inducement...

Nuwellis Announces $5 Million Private Placement and Warrant Inducement Transaction, Priced At-The-Market MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on advancing precision cardiorenal care in critical care settings, today announced that it has entered into a securities purchase agreement with an institutional and accredited investor (the “Investor”) for the purchase and sale of 994,537 shares (the “Shares”) of the Company’s common stock, $0.0001 par value (the “Common Stock”) or (pre-funde...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch